Shattuck Labs pivots to SL-325, raises ~$46M in private placement, faces Nasdaq bid-price notice

Shattuck Labs, Inc. (NASDAQ: STTK) - Quick take

What's happening inside: management has discontinued SL-172154, reallocated spending toward SL-325 (lead DR3 antagonist), plans to start Phase 1 enrollment in Q3 2025, reduced operating expense and cash burn, and executed a Private Placement (Aug 4, 2025) expected to provide upfront proceeds of ≈$46M (potential total ≈$103M including warrant exercises). The company received a Nasdaq notice on Aug 8, 2025 for minimum bid-price noncompliance and must regain a $1.00 closing bid under Nasdaq rules to avoid delisting risk.

Key facts & numbers
- Cash and cash equivalents (June 30, 2025): $50,467 (in thousands)
- Investments (June 30, 2025): $0 reported on balance sheet (investments matured during period); cash equivalents detail: $0.7M operating accounts, $15.8M money market funds, $34.0M U.S. government securities
- Total assets (June 30, 2025): $64,371 (in thousands)
- Total liabilities (June 30, 2025): $7,352 (in thousands)
- Stockholders' equity (June 30, 2025): $57,019 (in thousands)
- Accumulated deficit (June 30, 2025): $(407,880) (in thousands)
- Collaboration revenue: Three months ended 6/30/2025 = $0; Six months ended 6/30/2025 = $0 (vs $1,609 and $2,724 for comparable 2024 periods)
- Research & Development expense: Q2 2025 = $8,680; Q2 2024 = $19,239. Six months 2025 = $18,599; Six months 2024 = $35,503
- General & Administrative expense: Q2 2025 = $4,352; Q2 2024 = $5,332. Six months 2025 = $8,822; Six months 2024 = $10,227
- Loss from operations: Q2 2025 = $(13,032); Q2 2024 = $(22,962). Six months 2025 = $(27,421); Six months 2024 = $(43,006)
- Net loss: Q2 2025 = $(12,458); Q2 2024 = $(21,552). Six months 2025 = $(26,160); Six months 2024 = $(40,056)
- Net loss per share - basic & diluted: Q2 2025 = $(0.24); Q2 2024 = $(0.42). Six months 2025 = $(0.51); Six months 2024 = $(0.79)
- Weighted-average shares outstanding - basic & diluted: Q2 2025 = 51,002,247; Q2 2024 = 50,791,241
- Cash used in operating activities (six months ended 6/30/2025): $(22,463) (in thousands)
- Stock-based compensation (six months ended 6/30/2025): $3,611 (in thousands)
- Shares outstanding (as of Aug 7, 2025): 47,903,215
- Pre-funded warrants outstanding (as of 6/30/2025): 3,100,823 (still outstanding)
- Stock options outstanding (6/30/2025): 8,312,974; RSUs outstanding: 517,848

Subsequent event - Private Placement (Aug 4, 2025)
- Agreed issuance: 15,225,158 shares and pre-funded warrants to purchase up to 37,410,188 shares, plus common-stock warrants to purchase up to 52,635,346 shares (or pre-funded warrants in lieu)
- Purchase price: $0.8677 per share + warrant; pre-funded price $0.8676
- Expected upfront aggregate gross proceeds: ≈ $46 million (before fees). If all common warrants exercised, potential additional proceeds ≈ $57 million (total potential ≈ $103 million). Closing conditioned on FDA IND clearance for SL-325 and other conditions.

Positive aspects (income statement / operations)
- Material reduction in R&D and G&A vs prior year (R&D down ~47.6% YTD) driven by discontinuation of SL-172154 and workforce reductions - improved cash conservation.
- Net loss narrowed materially YoY (six months: $(26.2)M vs $(40.1)M), lowering near-term burn.
- Management states cash + equivalents are sufficient to fund operations into 2027 (pre-Private Placement); Private Placement proceeds extend runway materially (management expects funding into 2029 if fully exercised).
- SL-325 program advanced (NHP toxicology complete; Phase 1 enrollment planned Q3 2025) - R&D spend now concentrated on lead candidate.

Negative aspects (income statement / risks)
- No product revenue; collaboration revenue = $0 in 2025 periods - company remains pre-revenue and dependent on external financing or partnerships.
- Continued significant net losses and large accumulated deficit $(407.9)M - operating at a loss with ongoing R&D spend expected to continue.
- Cash used in operations remains material: $(22.5)M in first half of 2025, creating funding dependence.
- Potential dilution: large authorized share reserve increases, outstanding options (8.31M), RSUs, pre-funded warrants (3.1M), and the Private Placement (15.2M new shares + warrants) that could heavily dilute current holders if exercised.
- Nasdaq bid-price noncompliance notice (Aug 8, 2025) - must cure by Feb 4, 2026 (or seek additional compliance period) or face delisting risks, which could hurt liquidity and access to capital.
- Collaboration revenue that previously offset some costs in 2024 (Ono, ImmunoGen) has ended; future revenues are uncertain and milestone-based.

Bottom line
Shattuck Labs is pivoting into a concentrated development path around SL-325, trimming legacy program costs and reducing burn. That improved the income-statement trend and extended runway, but the company remains unprofitable, pre-revenue, and dependent on the Aug 4 Private Placement and/or additional financings. Key near-term watch items: successful closing and timing of the Private Placement, IND clearance/Phase 1 progress for SL-325, and resolution of the Nasdaq minimum-bid noncompliance.